LUPKYNIS Drug Patent Profile

Which patents cover Lupkynis, and when can generic versions of Lupkynis launch?

Lupkynis is a drug marketed by Aurinia and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-eight patent family members in forty countries.

The generic ingredient in LUPKYNIS is voclosporin. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the voclosporin profile page.

DrugPatentWatch^® Generic Entry Outlook for Lupkynis

Lupkynis was eligible for patent challenges on January 22, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 17, 2027. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LUPKYNIS

International Patents:	198
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LUPKYNIS

Paragraph IV (Patent) Challenges for LUPKYNIS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUPKYNIS	Capsules	voclosporin	7.9 mg	213716	8	2025-01-22

US Patents and Regulatory Information for LUPKYNIS

LUPKYNIS is protected by three US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurinia	LUPKYNIS	voclosporin	CAPSULE;ORAL	213716-001	Jan 22, 2021		RX	Yes	Yes
Aurinia	LUPKYNIS	voclosporin	CAPSULE;ORAL	213716-001	Jan 22, 2021		RX	Yes	Yes
Aurinia	LUPKYNIS	voclosporin	CAPSULE;ORAL	213716-001	Jan 22, 2021		RX	Yes	Yes			Y	Y
Aurinia	LUPKYNIS	voclosporin	CAPSULE;ORAL	213716-001	Jan 22, 2021		RX	Yes	Yes

International Patents for LUPKYNIS

When does loss-of-exclusivity occur for LUPKYNIS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Japan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LUPKYNIS around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20090130195
Argentina	036852	PRECONCENTRADO DE UNA MICROEMULSION DE ANALOGOS DE CICLOSPORINA, SU METODO DE PREPARACION Y METODOS PARA PRODUCIR INMUNOSUPRESION
South Korea	101006206
European Patent Office	1816138
Japan	2007051376	ELECTROLYTIC-POLISHING ASSEMBLY FOR ELECTROLYTICALLY POLISHING CONDUCTIVE LAYER, AND ELECTROPOLISHING METHOD
China	100497748
Tunisia	SN04070	NOVEL CYCLOSPORIN ANALOG MICROEMULSION PRECONCENTRATES

LUPKYNIS (voclosporin): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Executive Summary

LUPKYNIS (voclosporin) is an immunosuppressive calcineurin inhibitor approved by the U.S. Food and Drug Administration (FDA) in January 2021 for adjunctive treatment of active lupus nephritis (LN). Developed by Aurinia Pharmaceuticals Inc., LUPKYNIS addresses an unmet need in a niche but growing autoimmune therapy market. Its market potential is driven by increasing prevalence of lupus nephritis, favorable clinical profile, and limited competition. This report analyzes the investment landscape, market dynamics, and financial trajectory for LUPKYNIS, providing strategic insights for stakeholders.

---

1. Market Overview

Aspect	Details / Data
Prevalence of Lupus Nephritis	Affects approximately 60,000–90,000 patients in the U.S. alone (Source: Lupus Foundation of America, 2021).
Indication	Adjunctive treatment of active lupus nephritis in adults.
Market Size (2023)	Estimated U.S. LN market at ~$500–$600 million; global markets potentially up to $1.2 billion (est. growth 7–10% annually).
Key Drivers	Rising lupus prevalence, unmet therapeutic needs, approval of new drugs, expanding indications.

---

2. Clinical and Regulatory Dynamics

Factor	Details
Mechanism of Action	Calcineurin inhibition – reducing immune activation involved in LN.
Regulatory Milestones	FDA approval in Jan 2021; EMA marketing authorization in some regions pending.
Clinical Trials	Phase 3 AURORA 1 trial demonstrated superior efficacy and safety versus comparator.
Treatment Paradigm	Used along with standard-of-care (steroids, MMF).

3. Competitive Landscape

Drug	Manufacturer	Status	Notes
LUPKYNIS (voclosporin)	Aurinia Pharmaceuticals	Approved (2021)	First-in-class, targeted LN therapy.
Cyclosporine (various formulations)	Multiple	Off-label use	Older, less specific, higher toxicity.
Mycophenolate Mofetil (MMF)	Various	Standard of care	Expensive, with tolerability issues.
Belimumab (Benlysta)	GSK	Approved	Monoclonal antibody, first biologic for active LN.
Voclosporin vs. Others	Novel CV agent	Differentiated by efficacy and safety	Advantage in rapid onset and tolerability.

4. Investment Opportunities

Segmentation	Opportunities & Risks	Implications
Market Penetration	Focus on high-prescribing nephrologists and rheumatologists.	Potential to increase market share post-marketing.
Pricing Strategy	Premium pricing vs. broad insurance coverage.	Impact on revenue growth; reimbursement landscape critical.
Expansion Indications	Potential for use in other autoimmune diseases.	Could diversify revenue streams.
Global Licensing	Partnering with overseas firms for markets like Europe and Asia.	Accelerates growth and diversification.
Patent & Exclusivity	Patent expiration in 2030; data exclusivity until 2025–2028.	Opportunity window for accumulated revenue.

---

5. Financial Trajectory and Projections

Metric	2021 (post-launch)	2022	2023	2024 & beyond
Sales	$50–$100M	~$150M	~$250M	Steady growth aligning with market expansion
Market Share	10–15% of LN market	20–25%	30%	Dominant position with increased adoption
Growth Rate (YoY)	—	100%	66%	20–30% as saturation approaches
Expenses	R&D, marketing, manufacturing	Increased marketing & global expansion	Continued R&D investment in additional indications	Operating margins improving as scale gains
Breakeven Point	Estimated in 2023–2024	Based on sales performance	To be confirmed upon actual sales data	Expected profit margins of 15–25% by 2025

---

6. Market Entry Strategy & Risk Factors

Strategy Element	Approach	Risks
Pricing & Reimbursement	Collaborate with insurers, demonstrate value proposition	Reimbursement hurdles, payer resistance
Physician Adoption	Engage KOLs, education campaigns	Slow adoption, competition from biologics
Global Expansion	Partner with regional players	Regulatory delays, market differences
Pipeline Development	Investigate additional autoimmune indications	Clinical failure risk, resource allocation

7. Comparative Analysis of Cost-Effectiveness

Parameter	LUPKYNIS	Standard Care (MMF + Steroids)	Biologics (Belimumab)
Cost (annual)	~$30,000–$40,000	~$20,000–$25,000	~$40,000–$50,000
Efficacy (Trial Data)	Superior in reducing renal flares	Variable	Chronic management
Safety Profile	Favorable, fewer adverse events	Known toxicity profile	Well-established but costly

---

8. Regulatory and Policy Environment

Element	Implication
Pricing Pressure	Increasing insurance scrutiny on innovative drugs.
Orphan Drug Policies	Potential benefits for rare autoimmune indications.
Post-Marketing Commitments	Further data to expand indications could improve market size.

---

9. Future Outlook and Financial Trajectory

Scenario	Description	Potential Outcome
Optimistic	Rapid adoption, expanded indications, successful global licensing	>$1B revenue by 2027, high profit margins
Baseline	Steady growth within current indications, moderate market penetration	~$500–$700M revenue by 2026
Conservative	Slow adoption, reimbursement hurdles, competitive pressures	<$400M revenue by 2026

---

10. Key Success Factors

• Market Penetration: Robust efforts targeting nephrologists, rheumatologists.
• Pricing & Reimbursement: Securing favorable reimbursement pathways.
• Pipeline Expansion: Developing new indications and formulations.
• Global Outreach: Strategic alliances to expand internationally.
• Regulatory Navigation: Timely approvals and meeting post-market commitments.

---

Key Takeaways

• Market Potential: The global lupus nephritis market is poised for growth, with LUPKYNIS positioned as a first-in-class therapy. Estimated revenues could reach several hundred million dollars within five years, contingent on market adoption and expansion.
• Competitive Edge: LUPKYNIS’s efficacy and safety profile provide a competitive advantage over older immunosuppressants and biologics, especially in specific patient subgroups.
• Investment Risks: Reimbursement hurdles, slow physician adoption, patent expiries, and competitive pressures from biologics pose challenges.
• Strategy: Focused marketing, potential label expansions, global licensing deals, and strategic collaborations will be essential to maximize financial returns.
• Financial Outlook: Expect moderate to high revenue growth through 2025, with profitability hinging on market acceptance, pricing strategies, and pipeline success.

---

FAQs

Q1: What is the current market size for LUPKYNIS globally?
Estimated at ~$600 million in 2023, with potential to surpass $1 billion as adoption increases.

Q2: How does LUPKYNIS compare to biologics like Belimumab?
LUPKYNIS offers oral administration with a different mechanism, potentially presenting a more convenient option with a favorable safety profile, filling a niche in combination therapies.

Q3: What are the key barriers to market penetration?
Reimbursement policies, physician familiarity, competition from established therapies, and cost considerations.

Q4: Are there plans for indication expansion?
Yes, ongoing research explores additional autoimmune indications, which may extend LUPKYNIS’s market lifespan.

Q5: How will generic competition impact future revenues?
Patent protection until 2030, after which generic versions may erode market share; strategic patent filings and pipeline diversification will mitigate this risk.

---

References

[1] Lupus Foundation of America. (2021). Lupus Nephritis Statistics.
[2] Aurinia Pharmaceuticals. (2021). FDA Approval for LUPKYNIS.
[3] MarketResearch.com. (2023). Lupus Nephritis Global Market Size and Forecast.
[4] FDA. (2021). LUPKYNIS, voclosporin – Highlights of Prescribing Information.
[5] GSK. (2022). Belimumab (Benlysta) for Lupus Nephritis.

---

This comprehensive analysis equips clinicians, investors, and biopharma strategists with critical insights into LUPKYNIS’s market dynamics and financial trajectory, supporting informed decision-making.